文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

塞拉利昂初治与经治HIV感染者耐药突变流行率

Prevalence of drug resistance mutations among ART-naive and -experienced HIV-infected patients in Sierra Leone.
PubMed 文献 · J Antimicrob Chemother · 2019-01-01

该横断面研究纳入塞拉利昂弗里敦Connaught医院215例HIV感染成人,其中64例初治、151例经治。初治者治疗前耐药率为36.7%,经治者64.4%携带耐药相关突变;基于基因型敏感性评分,22.4%初治者和56%经治者对一线ART不耐受。

要点

  • 初治者治疗前耐药率达36.7%,以NNRTI耐药为主(22.4%)。
  • 经治者64.4%携带耐药相关突变,对NRTI和NNRTI耐药率分别达85.2%和96.7%。
  • 22.4%初治者和56%经治者对塞拉利昂一线ART不耐受。

核心结论

  • 塞拉利昂初治和经治HIV-1感染者中循环NRTI和NNRTI耐药变异流行率高,需实施HIVDR监测以指导国家ART指南。

研究设计与样本

  • 对逆转录酶、蛋白酶和整合酶区域测序,采用Stanford HIVDR数据库和WHO 2009突变列表判读。

主要发现

  • 初治组治疗前耐药率为36.7%,其中NRTI耐药14.2%、NNRTI耐药22.4%;最常见突变K103N(14.3%)、M184V(8.2%)、Y181C(4.1%)。
  • 经治组64.4%携带耐药相关突变,NRTI和NNRTI耐药总流行率分别为85.2%(52/61)和96.7%(59/61)。
  • 经治组最常见突变为K103N(40.7%)、M184V(28.8%)、D67N(15.3%)、T215I/F/Y(15.3%)。
  • 基于基因型敏感性评分,22.4%初治者和56%经治者对塞拉利昂一线ART不耐受。

关键数值与推荐

  • 初治组治疗前耐药率36.7%(NRTI 14.2%,NNRTI 22.4%),最常见突变K103N 14.3%、M184V 8.2%、Y181C 4.1%。
  • 经治组耐药相关突变流行率64.4%,NRTI耐药85.2%(52/61)、NNRTI耐药96.7%(59/61)。
  • 经治组最常见突变K103N 40.7%、M184V 28.8%、D67N 15.3%、T215I/F/Y 15.3%。
  • 基因型敏感性评分提示22.4%初治者和56%经治者对一线ART不耐受。

临床怎么用

  • 塞拉利昂初治和经治HIV感染者中NRTI/NNRTI耐药流行率高,应推行HIVDR监测以更新国家ART指南。
  • 对经治患者,尤其暴露时间较长者,应关注K103N、M184V等突变对一线ART疗效的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The aim of this study was to assess the prevalence of HIV drug resistance (HIVDR) in HIV-infected ART-naive and -experienced patients in Sierra Leone. PATIENTS AND METHODS: We conducted a cross-sectional study of HIV-positive adults aged ≥18 years at Connaught Hospital in Freetown, Sierra Leone in November 2017. Sequencing was performed in the reverse transcriptase, protease and integrase regions, and interpreted using the Stanford HIVDR database and WHO 2009 mutation list. RESULTS: Two hundred and fifteen HIV-infected patients were included (64 ART naive and 151 ART experienced). The majority (66%) were female, the median age was 36 years and the median ART exposure was 48 months. The majority (83%) were infected with HIV-1 subtype CRF02_AG. In the ART-naive group, the pretreatment drug resistance (PDR) prevalence was 36.7% (14.2% to NRTIs and 22.4% to NNRTIs). The most prevalent PDR mutations were K103N (14.3%), M184V (8.2%) and Y181C (4.1%). In the ART-experienced group, 64.4% harboured resistance-associated mutations (RAMs) and the overall prevalence of RAMs to NRTIs and NNRTIs was 85.2% (52/61) and 96.7% (59/61), respectively. The most prevalent RAMs were K103N (40.7%), M184V (28.8%), D67N (15.3%) and T215I/F/Y (15.3%). Based on the genotypic susceptibility score estimates, 22.4% of ART-naive patients and 56% of ART-experienced patients were not susceptible to first-line ART used in Sierra Leone. CONCLUSIONS: A high prevalence of circulating NRTI- and NNRTI-resistant variants was observed in ART-naive and -experienced HIV-1-infected patients in Sierra Leone. This necessitates the implementation of HIVDR surveillance programmes to inform national ART guidelines for the treatment and monitoring of HIV-infected patients in Sierra Leone.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Yendewa GA, Sahr F, Lakoh S, et al. Prevalence of drug resistance mutations among ART-naive and -experienced HIV-infected patients in Sierra Leone. J Antimicrob Chemother. 2019. PMID: 30989237. doi:10.1093/jac/dkz134

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。